Compare COFS & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COFS | FDMT |
|---|---|---|
| Founded | 1898 | 2013 |
| Country | United States | United States |
| Employees | 598 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.2M | 449.6M |
| IPO Year | 1995 | 2019 |
| Metric | COFS | FDMT |
|---|---|---|
| Price | $31.45 | $9.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $34.00 | $31.71 |
| AVG Volume (30 Days) | 54.0K | ★ 541.3K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $227,624,000.00 | $85,209,000.00 |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $4.47 | $70.28 |
| P/E Ratio | $34.42 | ★ N/A |
| Revenue Growth | 63.64 | ★ 230194.60 |
| 52 Week Low | $26.10 | $3.55 |
| 52 Week High | $33.58 | $12.34 |
| Indicator | COFS | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 57.79 |
| Support Level | $29.51 | $9.71 |
| Resistance Level | $32.43 | $10.80 |
| Average True Range (ATR) | 0.68 | 0.61 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 67.05 | 60.19 |
ChoiceOne Financial Services Inc is a full-service banking institution. It is engaged in the business of providing personal and business banking solutions, borrowing solutions, and treasury notes and bonds services. The bank's product and services portfolio consist of time, savings and demand deposits, safe deposit services, automated transaction machine services, commercial and consumer loans, commercial lending to business, industry, agricultural, construction, inventory, and real estate categories. Its primary market area is Kent, Muskegon, Newaygo, and Ottawa counties in western Michigan, and Lapeer, Macomb, and St. Clair counties in southeastern Michigan in the communities where the Bank's respective offices are located.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).